Kean Lewis signs contract extension with Bengaluru FC

first_img Press Trust of India BengaluruMay 16, 2019UPDATED: May 16, 2019 18:03 IST Kean Lewis signed a contract extension to keep him till 2019-20 at Bengaluru FC (@KeanFLewis Photo)HIGHLIGHTSKean Lewis signed a contract extension with Bengaluru FCKean Lewis will stay on with the ISL champions till 2019-20Kean Lewis said that he is “very happy to have signed”Bengaluru FC Thursday announced Kean Lewis’ contract renewal, signing a deal that will keep the winger at the club until the end of the 2019-20 campaign.The TATA Football Academy graduate was part of the Mahindra United academy where he played at various youth levels, and signed with Bengaluru ahead of the 2018-19 campaign.Twenty-six-year-old Kean claimed the assist for Erik Paartalu’s winner against ATK at the Fortress, and was instrumental in several appearances off the bench in Bengaluru’s run to the Indian Super League trophy.”I’m very happy to have signed on with Bengaluru FC for another season. I was given the opportunity to play in several positions last season, which shows that the coach has faith in me. It gives me more chances to play, which was a key factor in my decision.”Further to that, the team, the management, and the core of the club is intact, which bodes well for our chances of retaining the title and I’m really looking forward to that,” said Kean, after completing formalities on his one-year deal.UPDATE! Winger @KeanFLewis has signed an extension with the Blues, which will keep him at the club for another season. #MoreOfKean #WeAreBFC pic.twitter.com/u9oUmIHpiEBengaluru FC (@bengalurufc) May 16, 2019Carles Cuadrat, who has signed on with Bengaluru for two more seasons, said that he was happy to see Kean back in the fold.”We’re happy to offer Kean another year because he’s been an important player for us throughout the course of last season. Kean made a difference coming off the bench in crucial moments and whenever we needed him. As a player who understands the philosophy of this club and our style of play, we stand to benefit from having him as part of the squad for another year,” said Cuadrat.advertisementAlso Read | King’s Cup: Igor Stimac names 37 probables for preparatory campFor sports news, updates, live scores and cricket fixtures, log on to indiatoday.in/sports. Like us on Facebook or follow us on Twitter for Sports news, scores and updates.Get real-time alerts and all the news on your phone with the all-new India Today app. Download from Post your comment Do You Like This Story? Awesome! Now share the story Too bad. Tell us what you didn’t like in the comments Tags :Follow Kean LewisFollow contract extensionFollow Bengaluru FCFollow ISLFollow Indian Super League Kean Lewis signs contract extension with Bengaluru FCKean Lewis extended his contract with Bengaluru FC to tie him down to the Indian Super League champions till the end of the 2019-20 campaign.advertisement Nextlast_img read more

Read More

Not enough new antibiotics in the pipeline UN report warns

The report released today by the World Health Organization (WHO) says most of the drugs currently in the clinical pipeline are modifications of existing classes of antibiotics and are only short-term solutions. “Antimicrobial resistance is a global health emergency that will seriously jeopardize progress in modern medicine,” said WHO Director-General Tedros Adhanom in a press release. The report found very few potential treatment options for those antibiotic-resistant infections identified by WHO as posing the greatest threat to health, including drug-resistant tuberculosis which kills around 250,000 people each year. “There is an urgent need for more investment in research and development for antibiotic-resistant infections including TB, otherwise we will be forced back to a time when people feared common infections and risked their lives from minor surgery,” Mr. Adhanom said. In addition to multidrug-resistant tuberculosis, WHO has identified 12 classes of priority pathogens – some of them causing common infections such as pneumonia or urinary tract infections – that are increasingly resistant to existing antibiotics and urgently in need of new treatments. The report identifies 51 new antibiotics and biologicals in clinical development to treat priority antibiotic-resistant pathogens, as well as tuberculosis and the sometimes deadly diarrhoeal infection Clostridium difficile. Among all these candidate medicines, however, only eight are classed by WHO as innovative treatments that will add value to the current antibiotic treatment arsenal. There is a serious lack of treatment options for multidrug- and extensively drug-resistant M. tuberculosis and gram-negative pathogens, including Acinetobacter and Enterobacteriaceae (such as Klebsiella and E.coli) which can cause severe and often deadly infections that pose a particular threat in hospitals and nursing homes. The report also found that although oral antibiotics are essential for treatment outside hospitals or in resource-limited settings, few are in the pipeline. “Pharmaceutical companies and researchers must urgently focus on new antibiotics against certain types of extremely serious infections that can kill patients in a matter of days because we have no line of defence,” said Suzanne Hill, Director of the Department of Essential Medicines at WHO. To counter this threat, WHO and the Drugs for Neglected Diseases Initiative (DNDi) set up a research and development partnership. According to Mario Raviglione, Director of the WHO Global Tuberculosis Programme, research for tuberculosis is seriously underfunded, with only two new antibiotics for treatment of drug-resistant tuberculosis having reached the market in over 70 years. “If we are to end tuberculosis, more than $800 million per year is urgently needed to fund research for new anti-tuberculosis medicines,” he said. read more

Read More